Lexogen announced the successful completion of a major data generation project with Ochre Bio, producing extensive functional genomics datasets from primary human hepatocytes. The initiative processed over 120,000 samples using Lexogen’s proprietary extraction-free, high-resolution gene expression platform and NGS services.
Ochre Bio, which develops RNA medicines for chronic, under-treated liver diseases, uses these datasets— including gene perturbation and disease atlases—in its proprietary software platform OBELiX to predict causal pathways and prioritize therapeutic targets. The data thus underpins Ochre’s AI-driven discovery engine for RNA-based treatments.
Lexogen noted that its NGS services operate under cGLP guidelines and are built on technologies manufactured under ISO 13485 standards in Vienna. Its THOR and pooling technologies enabled extraction-free RNA-Seq at large scale, offering high consistency and resolution even for challenging sample types.
The completion of this sequencing project strengthens the data foundation for RNA therapy research and may accelerate discovery of novel treatments for liver disease, according to the companies.
